公开(公告)号：EP3484311B1

公开(公告)日：2023-12-06

申请号：EP17745586.2

申请日：2017-07-17

发明人： LEBRUN-BLASHKA, Sara ,  TROUP, John ,  CONTRACTOR, Nikhat

IPC分类号： A23L33/21 ,  A61K31/702 ,  A61K31/7016 ,  A23L2/52 ,  A61K31/07 ,  A61K31/197 ,  A61K31/198 ,  A61K31/28 ,  A61K31/355 ,  A61K31/375 ,  A61K31/401 ,  A61K31/405 ,  A61K31/4172 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/51 ,  A61K31/525

公开(公告)号：EP4281439A1

公开(公告)日：2023-11-29

申请号：EP22704251.2

申请日：2022-01-20

申请人： The Scripps Research Institute

发明人： BOLLONG, Michael ,  SCHULTZ, Peter ,  SHAO, Sida ,  CHATTERJEE, Arnab ,  CHEN, Jian ,  ZHANG, Nan

IPC分类号： C07D207/16 ,  C07D487/04 ,  A61P11/00 ,  A61K31/401

公开(公告)号：EP4267247A1

公开(公告)日：2023-11-01

申请号：EP21912051.6

申请日：2021-12-21

申请人： Church & Dwight Co., Inc.

发明人： ZIMMERMAN, Noah, Paul ,  WESCOTT, Amy

IPC分类号： A61P31/00 ,  A61P31/10 ,  A61K31/401 ,  A23K30/18 ,  C12N1/20

公开(公告)号：EP4180045A1

公开(公告)日：2023-05-17

申请号：EP20952613.6

申请日：2020-09-02

申请人： Laboratorios Silanes, S.A. de C.V.

发明人： OLLERVIDES RUBIO, Paola Yazmín ,  ESPINOZA LEÓN, Sixto Serafín ,  CUAHUTENCOS ESCOBAR, Ernesto ,  GONZÁLEZ CANUDAS, Jorge Alejandro

IPC分类号： A61K31/64 ,  A61K31/155 ,  A61K31/401 ,  A61P3/10

摘要： This invention relates to an innovative stable immediate release drug for the treatment, control, and better management of type 2 diabetes mellitus containing a sulfonylurea such as glimepiride, a dipeptidyl peptidase-4 (DPP4) inhibitor such as vildagliptin, and a biguanidine such as metformin. At the same time, this invention allows solving a set of important technological challenges in the manufacture of said drug product due to the physicochemical properties and the difference in dosage of the synergistic combination of the drugs.

公开(公告)号：EP4165021A1

公开(公告)日：2023-04-19

申请号：EP21731503.5

申请日：2021-06-10

申请人： EPICS THERAPEUTICS

发明人： DUTHEUIL, Guillaume

IPC分类号： C07D207/16 ,  A61K31/401 ,  A61P29/00

公开(公告)号：EP4129407A1

公开(公告)日：2023-02-08

申请号：EP22193148.8

申请日：2015-02-25

申请人： Achillion Pharmaceuticals, Inc.

发明人： GADHACHANDA, Venkat Rao ,  WANG, Qiuping ,  PAIS, Godwin ,  HASHIMOTO, Akihiro ,  CHEN, Dawei ,  WANG, Xiangzhu ,  ARARWAL, Atul ,  DESHPANDE, Milind ,  WILES, Jason Allan ,  PHADKE, Avinash S.

IPC分类号： A61P37/00 ,  A61K31/416 ,  A61K31/401 ,  C07D401/14 ,  C07D403/14

摘要： Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formulae X or VI, or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

公开(公告)号：EP2073788B9

公开(公告)日：2023-01-11

申请号：EP07867174.0

申请日：2007-09-28

发明人： MURRAY, Martha M.

IPC分类号： A61L26/00 ,  A61L24/10 ,  A61L27/54 ,  A61L31/04 ,  A61K45/06 ,  A61L27/24 ,  A61L27/38 ,  A61L27/36 ,  A61L27/50 ,  A61L27/56 ,  A61L27/58 ,  A61K38/39 ,  A61K31/401 ,  A61K35/17 ,  A61K35/19 ,  A61P19/02

公开(公告)号：EP4091620A1

公开(公告)日：2022-11-23

申请号：EP22179865.5

申请日：2019-01-30

申请人： AKER BIOMARINE ANTARCTIC AS

发明人： ELLEGÅRD, Katrine, Hvid ,  BAGGER, Christian, Lorentz ,  MYHREN, Finn ,  WIKLUND, Erik, Digman

IPC分类号： A61K35/612 ,  A61K38/01 ,  A23L33/10 ,  A61K35/60 ,  A23K10/22 ,  A23J3/34 ,  A23K20/147 ,  A23L33/18 ,  A61K31/04 ,  A61K31/131 ,  A61K31/198 ,  A61K31/401 ,  A61K31/4172 ,  A61K33/00 ,  A61K33/06 ,  A61K33/16 ,  A61K31/405

摘要： The present invention provides marine protein hydrolysates for use in nutraceuticals, functional foods, foods, beverages, and animal feeds.

公开(公告)号：EP3500252B1

公开(公告)日：2022-11-02

申请号：EP17757821.8

申请日：2017-08-16

发明人： GREENFIELD, Susan ,  GARCIA-RATES, Sara ,  MORAL, Jesus ,  COSANO, Roger

IPC分类号： A61K31/165 ,  A61K31/401 ,  A61K31/4045 ,  A61K38/06 ,  A61P25/28 ,  A61P25/00 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18

公开(公告)号：EP4066895A1

公开(公告)日：2022-10-05

申请号：EP20892362.3

申请日：2020-11-27

申请人： ONO Pharmaceutical Co., Ltd.

发明人： IWAKI, Yuzo ,  ENDO, Toshimitsu ,  KUSUMI, Kensuke

IPC分类号： A61P7/00 ,  A61P43/00 ,  C07D207/34 ,  C07D409/04 ,  C07D409/12 ,  C07D471/04 ,  C07D495/04 ,  C07D513/04 ,  C07D209/42 ,  C07D209/52 ,  A61K31/401 ,  A61K31/403 ,  A61K31/4045 ,  A61K31/407 ,  A61K31/429 ,  A61K31/437

摘要： An object of the present invention is to provide a pharmaceutical containing a compound having an agonist activity for LPA3 as an active ingredient. As a result of intensive studies, the inventors of the present invention have found a compound represented by the following general formula (IY):

wherein all symbols represent the same meaning as described in the specification, having an agonist activity for LPA3, as a substance capable of solving such a problem and the like, and completed the present invention. Since the compound represented by general formula (IY) of the present invention and the like have an agonist activity for LPA3, it can be used as an active ingredient of a preventive and/or therapeutic agent for essential thrombocythemia or reactive thrombocytosis.